First accredited in the 1980s, our fellowship program has received full accreditation by the Accreditation Council for Graduate Medical Education (ACGME). The Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta is affiliated with Emory University School of Medicine, which is ranked among the top research medical schools in the country by U.S.News & World Report.
There is funding for four new fellows each year to be fully supported throughout the three-year program. Additional years of research training, including application for the Masters of Science in Clinical Research (MSCR) program, are available for highly qualified candidates.
Comprehensive Cancer and Blood Disorders Program
The Aflac Cancer Center provides advanced diagnostic and clinical care, educational programs, psychosocial support and innovative treatment and research options for children and young adults. In addition, we offer exceptional pediatric imaging, surgical subspecialty and subspecialty support. Our multidisciplinary approach to care integrates the efforts of many pediatric professionals, including a 33-member family support team composed of:
- Nurse practitioners
- Social workers
- Child life specialists
- Music therapist
- Hospital teachers
- Financial coordinators
- Utilization review specialist
Blood and Marrow Transplant
As one of the top pediatric BMT programs in the country, we provide care that is uniquely designed to accommodate the full spectrum of a child’s needs with expertise in both autologous and allogeneic transplants.
In addition to treating malignant diseases, we are also proficient in treating a variety of nonmalignant diseases through transplant, such as bone marrow failure syndromes, hemoglobinopathies, metabolic disorders, immune deficiencies and histiocytic/hemophagocytic disorders.
Our team is recognized as a national leader in transplanting patients with sickle cell disease—we have cured more than 50 children.
We have more than 20 physicians who are highly skilled and experienced in treating children and young adults with all forms of cancer—from the most common to those rarely seen outside of the top pediatric centers. Our cancer programs include:
Brain and Spinal Cord Tumors—We have one of the largest pediatric brain tumor programs in the country, following more than 700 children and young adults with brain tumors each year.
Our program features advanced imaging and neurosurgery capabilities, such as magnetic resonance imaging (MRI); software and techniques; an intra-operative MRI (iMRI) system; positron emission tomography; (PET) scanning; Gamma Knife technology; and stereotactic radiosurgery and radiotherapy
Leukemia and Lymphoma—Our program offers a large team of providers with specialized expertise in treating all forms of leukemia and lymphoma, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma (NHL).
Each year, our program cares for approximately 125 newly diagnosed patients using a variety of treatment protocols, including BMT and Phase I and Phase II trials for patients whose cancer has relapsed or is not responding to treatment.
Solid Tumor—Our program consists of medical and research professionals dedicated to treating solid tumors and developing new treatments and cures for the future. We care for approximately 125 newly diagnosed patients with these forms of cancer each year.
Additionally, our solid tumor program is one of the only programs in the Southeast offering therapeutic MIBG to patients with neuroblastoma.
Since 2001, we have offered a multidisciplinary Cancer Survivorship Program to address the unique needs of childhood cancer survivors who are at least two years off therapy. Our program currently follows more than 1,500 childhood cancer survivors.
Additionally, our team developed SurvivorLink™—a revolutionary web-based tool for survivors and their care teams to access their electronic Survivor Healthcare Plan (SHP).
Bleeding and Clotting Disorders—In collaboration with Emory University School of Medicine, we follow more than 1,000 children and adults with bleeding disorders and approximately 200 with clotting disorders in our Comprehensive Hemostasis and Thrombosis Program. We treat a wide range of disorders, including hemophilia, thrombosis and von Willebrand disease.
Sickle Cell Disease–Our Sickle Cell Disease Program—the largest pediatric program in the country, with more than 1,700 active patients—offers comprehensive clinics, transfusional services, specialty clinics and inpatient care. In addition, we have innovative services and technology to manage—and even cure—sickle cell disease, such as Transcranial Doppler (TCD) screening to evaluate patients for stroke risk and eligibility for BMT.
As one of the most active institutions in the U.S. in regards to pediatric clinical trial enrollment, we strive to improve and enhance the quality of life for children and young adults by offering some of the most promising new cancer agents and treatments for children who have relapsed or who have difficult-to-treat cancers through early-phase clinical trials.
Additionally, we participate in a number of national collaborative research consortia geared toward the early clinical development of promising therapies for the treatment of cancer and blood disorders in children and young adults. Highlights include:
- One of 21 centers in the country participating in COG Phase I and Pilot Consortium research
- Among a small group of universities and children’s hospitals with access to Phase I and Phase II neuroblastoma clinical trials through New Approaches to Neuroblastoma Therapy (NANT)
- One of 17 sites in the country participating in the NIH-funded Transfusion Medicine and Hemostasis Research Network
- One of only eight centers in the country awarded funds to participate in the NIH Sickle Cell Clinical Research Network
- A member of the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium, whose members work together to develop and carry out clinical trials
- Among only a few pediatric centers in the country to offer MIBG therapy, a treatment option for patients with refractory or recurrent neuroblastoma and malignant pheochromocytoma
We offer three-year pediatric Hematology/Oncology fellowships in collaboration with Emory University School of Medicine. Emory is among the largest pediatric hematology/oncology training programs in the country and the premiere program in the Southeast.
Our goal is to train academically oriented hematologists/oncologists who will be involved in a lifetime of excellence in pediatric patient care, teaching and clinical, translational or basic research.
Additionally, we offer a psychology fellowship program. This one-year training program is affiliated with the Emory University School of Medicine Postdoctoral Fellowship Training Program in Professional Psychology.
As one of the largest childhood cancer and blood disorders centers in the country, we care for more than 400 newly diagnosed cancer patients each year and follow more than 2,500 patients with sickle cell disease, hemophilia and other blood disorders. In addition, we have performed more than 1,000 BMTs since our program's inception and follow more than 1,500 survivors through our Cancer Survivor Program.
The following are 2014 statistics:
- New childhood cancer cases: 421
- Active sickle cell disease patients: 1,735
- Hemostasis and thrombosis: 500
- Pediatric blood and marrow transplants (BMT) cases: 74
- Outpatient visits: 29,093
- Inpatient days: 17,704
More volume and outcome data
With services offered at three hospitals, Egleston, Hughes Spalding and Scottish Rite, the Aflac Cancer Center features:
- 54-bed inpatient facilities
- 10 specially designed rooms for blood and marrow transplantation (BMT)
- Outpatient clinics with full range of infusional services
- Onsite diagnostics, cell processing laboratory, surgical oncology and pharmacy services
- MIBG treatment room—we are one of only a handful of pediatrics centers in the U.S. to offer MIBG treatment
Take a photo tour of our facilities
Dual Campus Model
In 1998, Egleston Children's Health Care System and Scottish Rite Medical Center came together to form Children's Healthcare of Atlanta—one of the largest pediatric systems in the country. The merger of Egleston, the pediatric teaching affiliate of Emory University School of Medicine, and Scottish Rite, the private hospital, provides our fellows with a unique learning experience.
Our dual campus model allows fellows to interact with physicians and subspecialty colleagues in both private and academic settings affording them a real-world training experience. Additionally, our model contributes to some of the country's largest pediatric patient volumes, exposing fellows to more educational cases and greater research opportunities.
While physical locations may be different, our individual hematology/oncology inpatient and outpatient units operate under the same clinical practice standards and use the same electronic medical records allowing consistency across the two hospital campuses. Video conferencing also effectively links both campuses for meetings. Fellows will be on-service and on-call at one campus at a time to alleviate travel between campuses.
“The two campus provides more depth to the fellows' clinical experience. I feel that our learning is enhanced by exposure to the academic and private practice settings.” -Jonathan Metts, M.D., Fellow